V1RG1 Inhibitors
V1RG1 inhibitors represent a class of chemical compounds designed to interfere with the function of a specific biological target known as V1RG1. The V1RG1 protein is involved in a crucial biological process, which is fundamental for the normal operation of certain cellular activities. Inhibitors in this class are characterized by their ability to bind to the active site or another critical region of the V1RG1 protein. This binding disrupts the normal function of the protein, effectively modulating the natural course of its action within the cell. The design of V1RG1 inhibitors is a complex process that requires a deep understanding of the protein's structure and the key interactions that govern its activity. These inhibitors are often developed through a process of structure-activity relationship (SAR) studies, where variations in chemical structure are correlated with changes in the compound's ability to inhibit the target.
The molecular interaction between V1RG1 inhibitors and their target involves a range of non-covalent interactions such as hydrogen bonding, hydrophobic effects, van der Waals forces, and sometimes ionic bonds. These interactions are finely tuned to ensure a high degree of specificity towards the V1RG1 protein, with the goal of minimizing off-target effects that could affect other proteins with similar structures or functions. Researchers employ various techniques, including X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling, to elucidate the precise manner in which these inhibitors engage with the V1RG1 protein. The development of V1RG1 inhibitors also takes into consideration the pharmacokinetic and pharmacodynamic properties of these compounds, which are essential for their proper interaction with the target protein. Stability, solubility, and the ability to reach the site of the V1RG1 protein within the cellular context are all critical factors that influence the design and optimization of these inhibitors.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is a potent and selective inhibitor of CDK2, directly inhibiting its kinase activity by competing with ATP for binding to the enzyme, leading to cell cycle arrest at the G1 phase and hindering DNA replication and cell division. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine selectively inhibits CDK2 by competing with ATP for the ATP-binding site, effectively blocking the phosphorylation of CDK2's substrates and stalling the cell cycle progression at the G1-S transition. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits CDK2 by binding to the ATP pocket, preventing phosphorylation of substrates necessary for G1 to S phase transition in the cell cycle and leading to cell cycle arrest. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
Indirubin-3'-monoxime is a potent inhibitor of CDK2, disrupting CDK2's ability to phosphorylate target proteins, which is crucial for the progression of the cell cycle and the regulation of cell growth and proliferation. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine competes with ATP for binding to CDK2, inhibiting its kinase activity, which is essential for the regulation of the cell cycle, particularly the transition from the G1 phase to the S phase. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib tightly binds to CDK2, hindering its kinase activity, which results in an effective blockade of cell cycle progression and can induce apoptosis in certain cell types. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 inhibits CDK2 by binding to its ATP-binding site, leading to the suppression of CDK2 kinase activity and the subsequent arrest of the cell cycle, particularly affecting the S phase entry and progression. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a selective and potent inhibitor of CDK2, leading to the inhibition of CDK2-driven phosphorylation events and resulting in cell cycle arrest, particularly at the G1-S transition. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Milciclib binds competitively to the ATP pocket of CDK2, reducing its activity and consequently leading to the inhibition of cell cycle progression, especially during the G1 to S phase transition. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
LEE011 (Ribociclib) selectively inhibits CDK2 by competing with ATP for the active site, which results in a decrease in CDK2 activity and leads to cell cycle arrest at the G1-S checkpoint. | ||||||